Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells |
| |
Authors: | Marina Cardillo Boris Yankelevich Amithaba Mazumder R Lupu |
| |
Institution: | (1) Vincent T. Lombardi Cancer Center, Georgetown University, 3970 Reservoir Road, Washington, DC, 20007, USA, VC;(2) Bone Marrow Transplant Program, Georgetown University, 3970 Reservoir Road, Washington, DC, 20007, USA, US |
| |
Abstract: | The erbB-2 oncoprotein is overexpressed in 30% of tumors from breast and ovarian cancer patients and it is related to poor overall and
disease-free survival. In vitro studies on erbB-2-overexpressing cells have found a strong correlation between this oncogene overexpression and relative resistance to lymphokine-activated
killer (LAK) cell lysis. gp30/heregulin/NDF (neu differentiation factor), indirect activators of erbB-2, are able to induce a more differentiated phenotype on erbB-2-overexpressing, erbB-3- and/or erbB-4-positive breast cancer cells. We tested the ability of these highly homologous growth factors to stimulate LAK cell lysis
of breast cancer cells. Our experiments demonstrated a marked increase in LAK cell cytotoxicity towards an erbB-2-overexpressing, erbB-3-positive cell line by treatment of these cells with heregulin for 72 h. In contrast we did not observe any enhancement of
lysis of MCF-7, a cell line that does not overexpress erbB-2 and is positive for the erbB-3 and erbB-4 receptors, after treatment with heregulin. The increased lysis was associated with up-regulation of intercellular adhesion
molecule 1 (ICAM-1), down-regulation of erbB-2 and increased binding between breast cancer cells and LAK cells. Pre incubation of target (SKBR3) cells with blocking anti-ICAM-1
antibody completely abrogated the enhanced cytotoxicity. A similar effect was observed by pretreatment of the effector (LAK)
cells with antibodies directed against LFA-1, the receptor for ICAM-1. These results suggest the possible utilization of gp30/heregulin
in the treatment of breast cancer patients by its ability to stimulate patient immune responses.
Received: 6 March 1995 / Accepted: 7 June 1996 |
| |
Keywords: | Heregulin erbB-2 erbB-3 erbB-4 LAK |
本文献已被 SpringerLink 等数据库收录! |
|